Bond J S, Failla M L, Unger D F
J Biol Chem. 1983 Jul 10;258(13):8004-9.
The regulation of hepatic arginase (EC 3.5.3.1) activity was studied in diabetic rats fed ad libitum. Arginase activity in liver cytosol increased 2 to 3 days after injection of streptozotocin into rats and remained elevated (maximally 1.7-fold) 13 days postinjection. Radioimmunoassays indicated, however, that the amounts of immunoreactive arginase protein in livers of control and diabetic rats were similar. The specific activity of purified preparations of arginase from diabetic rats was approximately 1.5-fold higher than that from control rats. Manganese, a cofactor for arginase, was elevated by 4 days post-streptozotocin injection and remained elevated (maximally 1.6-fold) for at least 13 days. Most of the manganese in control and diabetic liver cytosols was associated with macromolecules and eluted with arginase activity upon gel filtration. These data establish that the enhanced arginase activity observed in diabetes is coincident with elevated cofactor concentration but not with elevated enzyme protein concentration.
对随意进食的糖尿病大鼠肝脏精氨酸酶(EC 3.5.3.1)活性的调节进行了研究。给大鼠注射链脲佐菌素后2至3天,肝脏胞质溶胶中的精氨酸酶活性增加,并在注射后13天保持升高(最高达1.7倍)。然而,放射免疫分析表明,对照大鼠和糖尿病大鼠肝脏中免疫反应性精氨酸酶蛋白的量相似。糖尿病大鼠精氨酸酶纯化制剂的比活性比对照大鼠高约1.5倍。精氨酸酶的辅助因子锰在注射链脲佐菌素后4天升高,并至少13天保持升高(最高达1.6倍)。对照和糖尿病肝脏胞质溶胶中的大部分锰与大分子结合,并在凝胶过滤时与精氨酸酶活性一起洗脱。这些数据表明,在糖尿病中观察到的精氨酸酶活性增强与辅助因子浓度升高一致,但与酶蛋白浓度升高无关。